152 related articles for article (PubMed ID: 38705774)
1. Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.
Limonte CP; Lamprea-Montealegre JA; Tuttle KR
Semin Nephrol; 2024 May; ():151520. PubMed ID: 38705774
[TBL] [Abstract][Full Text] [Related]
2. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.
Nee R; Yuan CM; Narva AS; Yan G; Norris KC
Nephrol Dial Transplant; 2023 Feb; 38(3):532-541. PubMed ID: 36264305
[TBL] [Abstract][Full Text] [Related]
3. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
4. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease.
Neumiller JJ; Alicic RZ; Tuttle KR
Semin Nephrol; 2023 May; 43(3):151427. PubMed ID: 37857231
[TBL] [Abstract][Full Text] [Related]
6. Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
Sridhar VS; Limonte CP; Groop PH; Heerspink HJL; Pratley RE; Rossing P; Skyler JS; Cherney DZI
Diabetologia; 2024 Jan; 67(1):3-18. PubMed ID: 37801140
[TBL] [Abstract][Full Text] [Related]
7. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
[TBL] [Abstract][Full Text] [Related]
8. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.
Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I
Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800
[TBL] [Abstract][Full Text] [Related]
9. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.
Tuttle KR; Wong L; St Peter W; Roberts G; Rangaswami J; Mottl A; Kliger AS; Harris RC; Gee PO; Fowler K; Cherney D; Brosius FC; Argyropoulos C; Quaggin SE;
Clin J Am Soc Nephrol; 2022 Jul; 17(7):1092-1103. PubMed ID: 35649722
[TBL] [Abstract][Full Text] [Related]
10. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
Shubrook JH; Neumiller JJ; Wright E
Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
[TBL] [Abstract][Full Text] [Related]
11. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
[TBL] [Abstract][Full Text] [Related]
12. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.
von Scholten BJ; Kreiner FF; Rasmussen S; Rossing P; Idorn T
Ther Adv Endocrinol Metab; 2022; 13():20420188221112490. PubMed ID: 35874312
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
14. Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.
Neumiller JJ; Alicic RZ; Tuttle KR
Clin Kidney J; 2024 Jan; 17(1):sfad285. PubMed ID: 38213492
[TBL] [Abstract][Full Text] [Related]
15. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.
Mottl AK; Nicholas SB
Am J Kidney Dis; 2024 Mar; 83(3):277-287. PubMed ID: 38142396
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
18. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
19. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
